Drug-induced Sweet's syndrome secondary to hepatitis C antiviral therapy

Int J Dermatol. 2008 Sep;47(9):957-9. doi: 10.1111/j.1365-4632.2008.03724.x.

Abstract

Pegylated interferon-alpha in combination with ribavirin currently represents the therapeutic standard for the hepatitis C virus infection. Interferon based therapy may be responsible for many cutaneous side effects. We report a case of drug-induced Sweet's syndrome secondary to hepatitis C antiviral therapy. To our knowledge, this is the first reported case of Sweet's syndrome in association with pegylated interferon-alpha therapy.

Publication types

  • Case Reports

MeSH terms

  • Administration, Oral
  • Biopsy, Needle
  • Dose-Response Relationship, Drug
  • Female
  • Follow-Up Studies
  • Hepatitis C, Chronic / diagnosis
  • Hepatitis C, Chronic / drug therapy*
  • Humans
  • Immunohistochemistry
  • Injections, Subcutaneous
  • Interferon alpha-2
  • Interferon-alpha / adverse effects*
  • Interferon-alpha / therapeutic use
  • Middle Aged
  • Prednisone / administration & dosage
  • Recombinant Proteins
  • Ribavirin / adverse effects*
  • Ribavirin / therapeutic use
  • Risk Assessment
  • Sweet Syndrome / chemically induced*
  • Sweet Syndrome / drug therapy
  • Sweet Syndrome / pathology
  • Treatment Outcome

Substances

  • Interferon alpha-2
  • Interferon-alpha
  • Recombinant Proteins
  • Ribavirin
  • Prednisone